2006
Greater vulnerability to the amnestic effects of ketamine in males
Morgan CJ, Perry EB, Cho HS, Krystal JH, D’Souza D. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187: 405-414. PMID: 16896964, DOI: 10.1007/s00213-006-0409-0.Peer-Reviewed Original ResearchConceptsAmnestic effectsProcessing of wordsGeneral cognitive functioningGreater performance decrementsGreater subjective senseGender differencesObjectivesThe current studyGreater vulnerabilityCognitive measuresCognitive differencesCognitive functioningPerceptual alterationsPerformance decrementsNMDA-R functionAttention dataMemory impairmentSubjective senseNegative symptomsCurrent studyFunctioningHVLTKetamine studiesAnxietyMemoryKetamine administration
2004
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004, 29: 1558-1572. PMID: 15173844, DOI: 10.1038/sj.npp.1300496.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyArousalAttentionBehaviorCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolFemaleHallucinogensHemodynamicsHumansHydrocortisoneInjections, IntravenousMaleMemory, Short-TermMental RecallPanicProlactinPsychiatric Status Rating ScalesPsychometricsPsychoses, Substance-InducedSpeechVerbal LearningConceptsCannabinoid receptor functionWord recallRecognition recallVerbal fluencyCognitive deficitsProspective safety dataNegative symptomsAbuse disordersHealthy individualsCounterbalanced studyMonths poststudyRecallPsychotomimetic effectsPsychotic disordersReceptor functionPsychosisEndogenous psychosesIndividualsDistractibilityFluencyTransient symptomsDisordersEndocrine effectsSafety dataAnxiety
1996
Noradrenergic mechanisms in stress and anxiety: I. preclinical studies
Bremner J, Krystal J, Southwick S, Charney D. Noradrenergic mechanisms in stress and anxiety: I. preclinical studies. Synapse 1996, 23: 28-38. PMID: 8723133, DOI: 10.1002/(sici)1098-2396(199605)23:1<28::aid-syn4>3.0.co;2-j.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderBrain regionsNoradrenergic brain systemsMultiple subcortical areasConsiderable preclinical evidenceLocus coeruleusBrain systemsNeural mechanismsStress disorderTarget brain regionsBehavioral manifestationsBrain functionPanic disorderStress exposureChronic stress resultsTurnover of norepinephrineSubcortical areasAnxietyPsychiatric disordersNoradrenergic systemLong-term alterationsNoradrenergic mechanismsNoradrenergic neuronsNorepinephrine releasePreclinical evidence
1990
Noradrenergic function in panic disorder.
Charney DS, Woods SW, Nagy LM, Southwick SM, Krystal JH, Heninger GR. Noradrenergic function in panic disorder. The Journal Of Clinical Psychiatry 1990, 51 Suppl A: 5-11. PMID: 2258377.Peer-Reviewed Original ResearchConceptsLocus ceruleusNoradrenergic functionPanic disorderBrain noradrenergic functionNoradrenergic neuronal activityPanic disorder patientsNoradrenergic neuronsPreclinical evidenceNatural courseNoradrenergic nucleusDevelopment of anxietyAnxiogenic effectsClinical investigationDisorder patientsNeuronal activityUncontrollable stressNeuron firingNonhuman primatesNeurodevelopmental perspectiveLaboratory animalsSystem regulationFear responsesDisordersAnxietyElectrical activationSerotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-Specific Drugs for Anxiety and Depressive Disorders. Annual Review Of Medicine 1990, 41: 437-446. PMID: 2139556, DOI: 10.1146/annurev.me.41.020190.002253.Peer-Reviewed Original Research
1989
Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects
Woods S, Krystal J, Heninger G, Charney D. Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sciences 1989, 45: 233-242. PMID: 2503670, DOI: 10.1016/0024-3205(89)90255-5.Peer-Reviewed Original ResearchConceptsHealthy human subjectsClonidine 2 mcg/Pulse rateEffects of alprazolamAnxiety-like effectsHuman subjectsRatings of anxietyOral alprazolamHypotensive effectVentilatory responseMcg/Noradrenergic systemBenzodiazepine receptorsAnxiolytic propertiesNeurobiologic mechanismsClonidineNew drugsAlprazolamAnxiety ratingsSubjective anxietyDrugsAnxietyNormal functioningNeural systemsUseful model system